Hong Kong · Delayed Price · Currency is HKD Sinopharm Group Statistics
Total Valuation
Sinopharm Group has a market cap or net worth of HKD 48.37 billion. The enterprise value is 165.45 billion.
| Market Cap | 48.37B |
| Enterprise Value | 165.45B |
Important Dates
The last earnings date was Friday, August 21, 2026.
| Earnings Date | Aug 21, 2026 |
| Ex-Dividend Date | Jun 23, 2026 |
Share Statistics
Sinopharm Group has 3.12 billion shares outstanding.
| Current Share Class | 1.34B |
| Shares Outstanding | 3.12B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -1.37% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 27.92% |
| Float | 1.27B |
Valuation Ratios
The trailing PE ratio is 5.91 and the forward PE ratio is 5.37. Sinopharm Group's PEG ratio is 1.84.
| PE Ratio | 5.91 |
| Forward PE | 5.37 |
| PS Ratio | 0.07 |
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.54 |
| P/FCF Ratio | 2.81 |
| P/OCF Ratio | 2.55 |
| PEG Ratio | 1.84 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.18, with an EV/FCF ratio of 9.62.
| EV / Earnings | 20.20 |
| EV / Sales | 0.25 |
| EV / EBITDA | 7.18 |
| EV / EBIT | 7.95 |
| EV / FCF | 9.62 |
Financial Position
The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.60.
| Current Ratio | 1.40 |
| Quick Ratio | 1.04 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 4.32 |
| Debt / FCF | 5.46 |
| Interest Coverage | 8.32 |
Financial Efficiency
Return on equity (ROE) is 8.04% and return on invested capital (ROIC) is 6.85%.
| Return on Equity (ROE) | 8.04% |
| Return on Assets (ROA) | 2.56% |
| Return on Invested Capital (ROIC) | 6.85% |
| Return on Capital Employed (ROCE) | 11.55% |
| Weighted Average Cost of Capital (WACC) | 3.47% |
| Revenue Per Employee | 7.30M |
| Profits Per Employee | 90,538 |
| Employee Count | 90,447 |
| Asset Turnover | 1.39 |
| Inventory Turnover | 7.97 |
Taxes
In the past 12 months, Sinopharm Group has paid 4.45 billion in taxes.
| Income Tax | 4.45B |
| Effective Tax Rate | 26.54% |
Stock Price Statistics
The stock price has decreased by -18.17% in the last 52 weeks. The beta is 0.44, so Sinopharm Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | -18.17% |
| 50-Day Moving Average | 16.69 |
| 200-Day Moving Average | 18.85 |
| Relative Strength Index (RSI) | 34.82 |
| Average Volume (20 Days) | 5,413,554 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sinopharm Group had revenue of HKD 660.27 billion and earned 8.19 billion in profits. Earnings per share was 2.62.
| Revenue | 660.27B |
| Gross Profit | 46.64B |
| Operating Income | 19.50B |
| Pretax Income | 16.78B |
| Net Income | 8.19B |
| EBITDA | 21.73B |
| EBIT | 19.50B |
| Earnings Per Share (EPS) | 2.62 |
Balance Sheet
The company has 35.84 billion in cash and 93.88 billion in debt, with a net cash position of -58.04 billion or -18.60 per share.
| Cash & Cash Equivalents | 35.84B |
| Total Debt | 93.88B |
| Net Cash | -58.04B |
| Net Cash Per Share | -18.60 |
| Equity (Book Value) | 157.40B |
| Book Value Per Share | 31.52 |
| Working Capital | 119.06B |
Cash Flow
In the last 12 months, operating cash flow was 18.99 billion and capital expenditures -1.79 billion, giving a free cash flow of 17.21 billion.
| Operating Cash Flow | 18.99B |
| Capital Expenditures | -1.79B |
| Depreciation & Amortization | 2.26B |
| Net Borrowing | -21.66B |
| Free Cash Flow | 17.21B |
| FCF Per Share | 5.51 |
Margins
Gross margin is 7.06%, with operating and profit margins of 2.95% and 1.24%.
| Gross Margin | 7.06% |
| Operating Margin | 2.95% |
| Pretax Margin | 2.54% |
| Profit Margin | 1.24% |
| EBITDA Margin | 3.29% |
| EBIT Margin | 2.95% |
| FCF Margin | 2.56% |
Dividends & Yields
This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 5.25%.
| Dividend Per Share | 0.80 |
| Dividend Yield | 5.25% |
| Dividend Growth (YoY) | 6.90% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 5.25% |
| Earnings Yield | 16.93% |
| FCF Yield | 35.57% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Sinopharm Group is 21.25, which is 38.35% higher than the current price. The consensus rating is "Buy".
| Price Target | 21.25 |
| Price Target Difference | 38.35% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 3.44% |
| EPS Growth Forecast (3Y) | 6.57% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sinopharm Group has an Altman Z-Score of 2.19 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.19 |
| Piotroski F-Score | 7 |